JW Therapeutics Sanghai co, ltd. logo

JW Therapeutics Sanghai co, ltd.

JW Therapeutics is a clinical stage biopharmaceutical company founded by Juno Therapeutics (now part of Celgene) and WuXi AppTec Group to focus on leading cell-based therapy technologies.

JW Therapeutics combines Junos world-class technology platform with WuXi AppTec Groups local expertise, R&D and manufacturing platform.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.jwtherapeutics.com
Founded2016
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
2F-B, No.227, Meisheng Rd.Pilot Free Trade Zone 200131
Shanghai
China
Email
Contact Number

JW Therapeutics is a clinical stage biopharmaceutical company founded by Juno Therapeutics (now part of Celgene) and WuXi AppTec Group to focus on leading cell-based therapy technologies.

JW Therapeutics combines Junos world-class technology platform with WuXi AppTec Groups local expertise, R&D and manufacturing platform.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/jw-therapeutics” connections=”true” suffix=””]

In March 2018, JW Therapeutics raised $90 Mn in a series A round. Consortium led by leading global investors Temasek, Sequoia Capital China, and YuanMing Capital is joined by a lineup of other investors, including Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, Shiyu Capital, LVC Super Unicorn Fund, and existing investors WuXi AppTec Group, and Juno Therapeutics.